[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sickle-cell\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sickle-cell":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,79,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100338382","genotype--phenotype-correlation-of-pklr-variants-with-pyruvate-kinase-23-diphosphglycerate-and-adenosine-triphosphate-activities-in-red-blood-cells-of-people-with-sickle-cell-disease-100338382",false,"NCT03685721","Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate Activities in Red Blood Cells of People With Sickle Cell Disease","Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and ATP Activities in Red Blood Cells of Patients With Sickle Cell Disease","* INCLUSUION CRITERIA:\n* Between 18 and 80 years of age\n* African or of African descent\n* Capacity to consent is required\n\nEXCLUSION CRITERIA:\n\n* Self-reported history of blood transfusion within the last 8 weeks\n* Known to have pyruvate kinase deficiency and be on AG348\n* All volunteers will undergo the consent process under this protocol to allow for eligibility assessment. Once they have been consented to participate, they will undergo procedures per Protocol.",true,"ALL","18 Years","80 Years",{"count":21,"type":22},800,"ESTIMATED","OBSERVATIONAL","Background:\n\nSome people with the same disorder on a genetic level have more complications than others. Researchers want to look for a link between the PKLR gene and sickle cell disease (SCD) symptoms. The PKLR gene helps create a protein, called pyruvate kinase that is essential in normal functioning of the red blood cell. Differences in the PKLR gene, called genetic variants, may cause some changes in the pyruvate kinase protein and other proteins, that can affect functioning of the red blood cell adding to the effect of SCD. Researchers can study these differences by looking at DNA (the material that determines inherited characteristics).\n\nObjective:\n\nTo study how the PKLR gene affects sickle cell disease.\n\nEligibility:\n\nAdults ages 18-80 of African descent. They may have sickle cell disease or not. They must not have had a transfusion recently or have a known deficiency of pyruvate kinase. They cannot be pregnant.\n\nDesign:\n\nParticipants will be screened with questions.\n\nParticipants will have blood drawn by needle in an arm vein. The blood will be genetically tested. Not much is known about how genes affect SCD, so the test results will not be shared with participants or their doctors.\n\n...",[26,27,28],"Sickle Cell","PKLR Variants","Adenosine Triphosphate Activities",[30,31,32,33,34],"ATP","Trait","GDP","Genetics","Natural History","RECRUITING","2026-06-05",{"date":38,"type":39},"2026-06-08","ACTUAL",{"date":41,"type":39},"2018-10-11",{"date":43,"type":22},"2026-07-01",{"name":45,"class":46},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":47},"100634521","development-of-a-provider-focused-intervention-to-improve-health-outcomes-in-pediatric-sickle-cell-disease-100634521","NCT07540767","Development of a Provider-Focused Intervention to Improve Health Outcomes in Pediatric Sickle Cell Disease","Inclusion Criteria:\n\n* Licensed health care provider (HCP) who provides care to youth with SCD\n* HCP employed by Connecticut Children's, Yale New Haven Children's Hospital, or Children's Hospital of Philadelphia and primary work area is Hematology\u002FOncology\n\nExclusion Criteria:\n\n* HCP who does not provide care to youth with SCD\n* HCP is a medical trainee, not including fellows\n* HCP not employed by CT Children's, Yale New Haven Children's Hospital, or Children's Hospital of Philadelphia\n* Not fluent in English",{"count":55,"type":22},30,"INTERVENTIONAL",[58],"NA","The goal of this interventional study is to learn about the impact of an intervention for health care providers that teaches individuation and perspective-taking (IPT) skills to enhance patient-centered communication in pediatric sickle cell disease (SCD). The main question it aims to answer is:\n\nDoes an intervention that teaches individuation and perspective-taking (IPT) skills to pediatric sickle cell disease (SCD) health care providers (HCPs) enhance patient-centered communication?\n\nResearchers will compare the IPT intervention to a control group who will receive education about SCD pain management to see if the IPT intervention improves patient-centered communication.\n\nParticipants will complete baseline surveys and then be randomly assigned into the intervention or control group. After completing their assigned session (IPT training or education), they will be asked to complete the same surveys as completed at baseline.",[61,62,63,26,64],"Sickle Cell Disease","Sickle Cell Anemia in Children","Sickle Cell Disease (SCD)","Sickle Cell Anemia (HbSS)",[66,67],"sickle cell","pediatrics","NOT_YET_RECRUITING","2026-04-24",{"date":71,"type":39},"2026-04-29",{"date":73,"type":22},"2027-09-01",{"date":75,"type":22},"2030-06-30",{"name":77,"class":78},"Connecticut Children's Medical Center","OTHER",{"id":80,"slug":4,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":56,"phases":87,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":47},"100584218","NCT06886477","Sickle Cell, Pain and Mediterranean Diet","Exploring the Mediterranean Diet as A Promising Approach for Alleviating Chronic Pain in Sickle Cell Disease","MedSCP","Inclusion Criteria:\n\n* Sickle Cell Disease Diagnosis\n* Chronic non-vaso-occlusive pain experienced on average ≥ 3 days per week for \\> 6 months (based on a response of \"Most days,\" \"Every day,\" or \"Some days\" and not \"Never\" to the question \"In the past 6 months, how often have you had pain?\")\n* Ability to speak, read, write, and understand English\n* A Mediterranean Eating Pattern for Americans (MEPA-III) score \\\u003C13, indicating that they do not follow a Mediterranean diet.\n\nExclusion Criteria:\n\n* Having taken systemic antimicrobials (to treat an infection in the previous 4 weeks)\n* History of colon cancer or inflammatory bowel disease (given potential untoward effects on the gut microbiome)\n* History of Clostridium difficile infection in the preceding 12 weeks; (4) unable to agree to maintain physical activity at the current level for the duration of the study\n* Currently following a Mediterranean diet, vegan diet, or dietary restrictions (e.g., religious, food intolerance\u002Fallergy) that preclude adoption of a Mediterranean diet\n* Lack of access to a space to safely store and reheat food items\n* Living in a facility that provides meals.\n* Pregnancy or breastfeeding\n* More than 7 in-patient hospital stays in the last year\n* Currently receiving dialysis treatment",{"count":55,"type":22},[58],"The goal of this study is to compare pain levels in individuals with Sickle Cell Disease while following the Mediterranean Diet to pain levels while following their usual diet.",[26,61,90,91],"Sickle Cell Disease Without Crisis","Mediterranean Diet",[66,93,94,95,96],"sickle cell disease","sickle cell pain","diet","Mediterranean diet","2026-04-01",{"date":99,"type":39},"2026-04-02",{"date":101,"type":39},"2025-05-01",{"date":103,"type":22},"2026-12-31",{"name":105,"class":78},"University of Illinois at Chicago",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":47},"100593034","impact-of-regional-anesthesia-on-inflammatory-mechanisms-during-vaso-occlusive-crisis-in-sickle-cell-patients-100593034","NCT07001189","Impact of Regional Anesthesia on Inflammatory Mechanisms During Vaso-occlusive Crisis in Sickle Cell Patients","ALRCVO-MP","Inclusion Criteria:\n\n* patients adult \\>18 years\n* patients with vaso-occlusive crisis\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Blood transfusion within the last 3 months\n* Lack of affiliation with the French social security system\n* Protected individuals",{"count":114,"type":22},34,"Sickle cell disease is a chronic disease characterized by multiple vaso-occlusive complications. The basic treatment for patients with a vaso-occlusive crisis (VOC) is based on adequate hydration, oxygen therapy and pain control. Loco Regional Anesthesia (LRA) is one of the major treatments in resuscitation anesthesia for both anesthesia and analgesia. LRA allows effective and almost immediate pain control by blocking nerve afferents in a given area. LRA could decrease the inflammatory response during crises and accelerate resolution of the crisis.",[26,61,117],"Vaso-Occlusive Crises",[119,120,117],"Loco-regional anesthesia","inflammation","2025-05-23",{"date":123,"type":39},"2025-06-03",{"date":125,"type":39},"2025-02-05",{"date":127,"type":22},"2027-02-05",{"name":129,"class":78},"Centre Hospitalier Universitaire de la Guadeloupe"]